24 | AntiemeticsIBA
06/2021
-
01/2002 |
22 | EmeticsIBA
06/2021
-
01/2002 |
20 | Cisplatin (Platino)FDA LinkGeneric
01/2020
-
01/2003 |
15 | Serotonin (5 Hydroxytryptamine)IBA
06/2021
-
03/2004 |
13 | Substance PIBA
06/2021
-
09/2005 |
12 | CannabinoidsIBA
01/2020
-
01/2002 |
10 | Palonosetron (Aloxi)FDA Link
06/2021
-
01/2014 |
9 | Dopamine (Intropin)FDA LinkGeneric
06/2021
-
01/2005 |
8 | netupitantIBA
06/2021
-
04/2015 |
8 | Neurotransmitter Agents (Neurotransmitter)IBA
05/2021
-
09/2005 |
8 | RimonabantIBA
12/2019
-
01/2002 |
7 | Nifedipine (Adalat)FDA LinkGeneric
06/2021
-
01/2014 |
6 | 5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA
06/2021
-
01/2014 |
5 | Dronabinol (THC)FDA LinkGeneric
01/2020
-
01/2002 |
5 | GR 73632IBA
12/2019
-
06/2008 |
5 | TachykininsIBA
04/2015
-
06/2008 |
4 | Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA
01/2021
-
01/2013 |
4 | Dantrolene (Dantrium)FDA LinkGeneric
01/2021
-
01/2014 |
4 | Dopamine Agonists (Dopamine Agonist)IBA
11/2020
-
01/2005 |
4 | EndocannabinoidsIBA
01/2014
-
09/2005 |
3 | U 0126 (UO 126)IBA
06/2021
-
01/2021 |
3 | bisindolylmaleimide IIBA
01/2021
-
09/2018 |
3 | QuinpiroleIBA
01/2021
-
01/2005 |
3 | CB1 Cannabinoid Receptor (CB1 Receptor)IBA
12/2019
-
01/2005 |
3 | 3- (2- hydroxy- 4- (1,1- dimethylheptyl)phenyl)- 4- (3- hydroxypropyl)cyclohexanolIBA
12/2019
-
01/2003 |
3 | Tropisetron (Navoban)IBA
08/2017
-
01/2009 |
3 | FPL 64176IBA
01/2017
-
01/2014 |
3 | CalciumIBA
01/2017
-
01/2014 |
3 | Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
04/2016
-
01/2014 |
3 | Amlodipine (Norvasc)FDA LinkGeneric
05/2015
-
01/2014 |
3 | ApomorphineFDA Link
05/2014
-
01/2005 |
3 | Arachidonic Acid (Vitamin F)IBA
09/2010
-
01/2002 |
3 | anandamide (arachidonylethanolamide)IBA
01/2006
-
06/2005 |
2 | Proteins (Proteins, Gene)FDA Link
01/2021
-
01/2013 |
2 | 2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA
01/2021
-
09/2018 |
2 | Ion Channels (Ion Channel)IBA
11/2020
-
01/2014 |
2 | EnzymesIBA
11/2020
-
09/2005 |
2 | resiniferatoxinIBA
01/2020
-
01/2014 |
2 | 5-Hydroxytryptophan (5 Hydroxytryptophan)IBA
12/2019
-
03/2004 |
2 | CB2 Cannabinoid ReceptorIBA
12/2019
-
06/2007 |
2 | 2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA
09/2018
-
01/2014 |
2 | leukotriene D4 receptor (cysteinyl leukotriene receptor)IBA
08/2017
-
02/2010 |
2 | pranlukastIBA
08/2017
-
02/2010 |
2 | LeukotrienesIBA
08/2017
-
02/2010 |
2 | ThapsigarginIBA
01/2017
-
04/2016 |
2 | L-Type Calcium Channels (Dihydropyridine Receptor)IBA
05/2015
-
01/2014 |
2 | Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA
04/2015
-
01/2014 |
2 | Messenger RNA (mRNA)IBA
01/2013
-
01/2010 |
2 | ProstaglandinsIBA
09/2010
-
09/2005 |
2 | Dexamethasone (Maxidex)FDA LinkGeneric
01/2009
-
09/2005 |
2 | Mesylates (Mesylate)IBA
06/2007
-
01/2003 |
2 | Cannabinoid Receptors (Cannabinoid Receptor)IBA
06/2007
-
01/2005 |
2 | glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA
09/2005
-
01/2003 |
1 | temsirolimusFDA Link
01/2022 |
1 | Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
06/2021 |
1 | N- (4- methoxybenzyl)- N'- (5- nitro- 1,3- thiazol- 2- yl)ureaIBA
06/2021 |
1 | Glycogen Synthase Kinase 3IBA
06/2021 |
1 | SB 216763IBA
06/2021 |
1 | MK 2206IBA
06/2021 |
1 | perifosineIBA
06/2021 |
1 | Dopamine D2 Receptors (Dopamine D2 Receptor)IBA
01/2021 |
1 | mu Opioid Receptors (mu Opioid Receptor)IBA
01/2021 |
1 | Histamine (Histamine Dihydrochloride)FDA Link
01/2021 |
1 | Sulpiride (neogama)IBA
01/2021 |
1 | 2,4,6- trimethyl- N- (meta- 3- trifluoromethylphenyl)benzenesulfonamideIBA
01/2021 |
1 | Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
01/2021 |
1 | Protein Kinase CIBA
01/2021 |
1 | 1- (6- ((3- methoxyestra- 1,3,5(10)- trien- 17- yl)amino)hexyl)- 1H- pyrrole- 2,5- dioneIBA
01/2021 |
1 | Type C PhospholipasesIBA
01/2021 |
1 | Dopamine Receptors (Dopamine Receptor)IBA
11/2020 |
1 | G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
11/2020 |
1 | LigandsIBA
11/2020 |
1 | Copper Sulfate (Sulfate, Copper)FDA Link
01/2020 |
1 | Anti-Asthmatic Agents (Antiasthmatic Drugs)IBA
08/2017 |
1 | palosentron drug combination netupitantIBA
01/2017 |
1 | Cholinergic Agents (Cholinergics)IBA
01/2017 |
1 | Sarcoplasmic Reticulum Calcium-Transporting ATPasesIBA
01/2017 |
1 | ProdrugsIBA
04/2016 |
1 | 4- methyl- 4'- (3,5- bis(trifluoromethyl)- 1H- pyrazol- 1- yl)- 1,2,3- thiadiazole- 5- carboxanilideIBA
04/2016 |
1 | Inositol (Myoinositol)IBA
04/2016 |
1 | RyanodineIBA
04/2016 |
1 | Serotonin ReceptorsIBA
04/2016 |
1 | Phosphotransferases (Kinase)IBA
04/2015 |
1 | Protein Kinases (Protein Kinase)IBA
04/2015 |
1 | Protein Kinase C-alphaIBA
04/2015 |
1 | (4- (m- Chlorophenylcarbamoyloxy)- 2- butynyl)trimethylammonium ChlorideIBA
05/2014 |
1 | Pilocarpine (Ocusert)FDA LinkGeneric
05/2014 |